ecancermedicalscience

Research

Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers

15 Dec 2020
Milena Perez Mak, Fatima Solange Pasini, Lixia Diao, Fabyane O Teixeira Garcia, Tiago Kenji Takahashi, Denyei Nakazoto, Renata Eiras Martins, Cristiane Maria Almeida, Marco Aurelio Vamondes Kulcsar, Valdelania Aparecida Lamounier, Emily Montosa Nunes, Isabela Cristina de Souza, Marcio Ricardo Taveira Garcia, Alex Vieira Amadio, Sheila Aparecida C Siqueira, Igor Moysés Longo Snitcovsky, Laura Sichero, Jing Wang, Gilberto de Castro Jr

Background: Cisplatin-based chemoradiation (CCRT) offers locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients high local control rate, however, relapses are frequent. Our goal was to evaluate if association of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, with CCRT improved response rate (RR) and associated biomarkers.

Methods: This phase II trial included patients with unresectable locally advanced (LA) oropharynx (OP) squamous cell carcinoma. CCRT began after 2 weeks of VPA (P1). Primary goal was RR at 8 weeks after chemoradiation (CRT) VPA (P2). Biomarkers included microRNA (miR) polymerase chain reaction (PCR)-array profiling in plasma compared to healthy controls by two-sample t-test. Distribution of p-values was analysed by beta-uniform mixture. Findings were validated by real-time PCR quantitative polymerase chain reaction (qPCR) for selected miRs in plasma and saliva. p16, HDAC2 and RAD23 Homolog B, Nucleotide Excision Repair Protein (HR23B) tumour immunohistochemistry were evaluated.

Results: Given significant toxicities, accrual was interrupted after inclusion of ten LA p16 negative OP patients. All were male, smokers/ex-smokers, aged 41–65 and with previous moderate/high alcohol intake. Nine evaluable patients yielded a RR of 88%. At false discovery rate of 5%, 169 miRs were differentially expressed between patients and controls, including lower expression of tumour suppressors (TSs) such as miR-31, -222, -let-7a/b/e and -145. miR-let-7a/e expression was validated by qPCR using saliva. A HDAC2 H-score above 170 was 90% accurate in predicting 6-month disease-free survival.

Conclusions: VPA and CRT offered high RR; however, with prohibitive toxicities, which led to early trial termination. Patients and controls had a distinct pattern of miR expression, mainly with low levels of TS miRs targeting Tumor protein P53 (TP53). miR-let-7a/e levels were lower in patients compared to controls, which reinforces the aggressive nature of such tumours (NCT01695122).

Related Articles

Babita Kataria, Aparna Sharma, Bivas Biswas, Sameer Bakhshi, Deepam Pushpam
Akhil Kapoor, Vanita Noronha, Amit Joshi, Vijay M Patil, Nandini Menon, Rajesh Bollam, Vikas Talreja, Supriya Goud, Sucheta More, Leena Solanki, Srushti Shah, Anuradha Chougule, Abhishek Mahajan, Kumar Prabhash
Adriana Regina Gonçalves Ribeiro, Marcela Marineli Salvadori, Louise de Brot, Graziele Bovolin, Henrique Mantoan, Felipe Ilelis, Mariana Rezende, Nayra Soares do Amaral, Solange Moraes Sanches, Joyce Maria Lisboa Maya, Elizabeth Santana dos Santos, Ronaldo Pereira, Fabrício de Souza Castro, João Paulo da Nogueira Silveira Lima, Andrea Paiva Gadelha Guimarães, Glauco Baiocchi, Alexandre André Balieiro Anastácio da Costa
Severyn Ferneza, Markiyan Fetsych, Roman Shuliak, Halyna Makukh, Natalia Volodko, Roman Yarema, Tara Fetsych